Ordering Recommendation

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out tapentadol exposure. For follow-up testing of a presumptive result, Tapentadol, Urine, Quantitative (2003128) is preferred.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Random urine.

Specimen Preparation

Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL)

Storage/Transport Temperature

Room temperature.

Unacceptable Conditions

Breast milk. Pharmaceutical preparation. Specimens exposed to repeated freeze/thaw cycles.

Remarks
Stability

Ambient: 1 week: Refrigerated: 1 month; Frozen: 1 month

Methodology

Qualitative Enzyme Immunoassay/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-4 days

Reference Interval

Interpretive Data

Methodology: Immunoassay

Positive Cutoff: 200 ng/mL

Compliance Category

Modified FDA

Note

If the specimen screens positive, then Confirmation/Quantitation by LC-MS/MS (ARUP test code 2003128) will be added to confirm result. Additional charges apply.

Hotline History

N/A

CPT Codes

80307; if reflexed, add 80372 (Reflexed Alt Code: G0480 )

Components

Component Test Code* Component Chart Name LOINC
2012212 Screen, Urine Interpretation 54247-2
2012295 Tapentadol Screen, Urine 72485-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Nucynta
  • Tapentadol, Qualitative
Tapentadol Urine Screen with Reflex to Quantitation